DUBLIN, Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in two upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. The conferences, presentation times and speakers include:
- Cowen and Company 33rd Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2013 at 8:40 a.m. EST/1:40 p.m. GMT. Kathryn Falberg, executive vice president and chief financial officer, will provide a business update.
- Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 12, 2013 at 9:00 a.m. EST/2:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide a business update.
An archived version of each webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc
For Investors, Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., +1-650-496-2717, For Media, Ami Knoefler, Executive Director, Corporate Communications, Jazz Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., +1-650-496-2947
